Shares of Momenta Pharmaceuticals (MNTA) tumbled 14.24% to .55 in the early trade, hit by stiff competition from Teva Pharmaceutical Industries (TEVA). Israel-based Teva is one step closer to launching a generic version of blood-thinner Lovenox, as the US FDA completed its review of the drug maker's application. As of now, Momenta and its partner Novartis AG (NVS) market the only generic version of Lovenox in the United States, according to wire reports.
No comments:
Post a Comment